Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;164(4):846-859.
doi: 10.1016/j.chest.2023.05.036. Epub 2023 Jun 17.

Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease

Sarah A R Siegel  1 , David E Griffith  2 , Julie V Philley  2 , Barbara A Brown-Elliott  2 , Amanda E Brunton  3 , Peter E Sullivan  3 , Cristina Fuss  3 , Luke Strnad  3 , Richard J Wallace Jr  2 , Kevin L Winthrop  3
Affiliations

Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease

Sarah A R Siegel et al. Chest. 2023 Oct.

Abstract

Background: Mycobacterium abscessus is the second most common nontuberculous mycobacterium respiratory pathogen and shows in vitro resistance to nearly all oral antimicrobials. M abscessus treatment success is low in the presence of macrolide resistance.

Research question: Does treatment with amikacin liposome inhalation suspension (ALIS) improve culture conversion in patients with M abscessus pulmonary disease who are treatment naive or who have treatment-refractory disease?

Study design and methods: In an open-label protocol, patients were given ALIS (590 mg) added to background multidrug therapy for 12 months. The primary outcome was sputum culture conversion defined as three consecutive monthly sputum cultures showing negative results. The secondary end point included development of amikacin resistance.

Results: Of 33 patients (36 isolates) who started ALIS with a mean age of 64 years (range, 14-81 years), 24 patients (73%) were female, 10 patients (30%) had cystic fibrosis, and nine patients (27%) had cavitary disease. Three patients (9%) could not be evaluated for the microbiologic end point because of early withdrawal. All pretreatment isolates were amikacin susceptible and only six isolates (17%) were macrolide susceptible. Eleven patients (33%) were given parenteral antibiotics. Twelve patients (40%) received clofazimine with or without azithromycin as companion therapy. Fifteen patients (50%) with evaluable longitudinal microbiologic data demonstrated culture conversion, and 10 patients (67%) sustained conversion through month 12. Six of the 33 patients (18%) demonstrated mutational amikacin resistance. All were patients using clofazimine or clofazimine plus azithromycin as companion medication(s). Few serious adverse events occurred for ALIS users; however, reduction of dosing to three times weekly was common (52%).

Interpretation: In a cohort of patients primarily with macrolide-resistant M abscessus, one-half of the patients using ALIS showed sputum culture conversion to negative findings. The emergence of mutational amikacin resistance was not uncommon and occurred with the use of clofazimine monotherapy.

Trial registry: ClinicalTrials.gov; No.: NCT03038178; URL: www.

Clinicaltrials: gov.

Keywords: Mycobacterium abscessus; amikacin liposome inhalation suspension; nontuberculous mycobacteria lung disease.

PubMed Disclaimer

Conflict of interest statement

Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: D. E. G. received support as a consultant from Insmed, Inc., AN2 Therapeutics, and Paratek Pharmaceuticals and received research support from Insmed, Inc. J. V. P. received support as part of advisory boards for Insmed, Inc., AN2 Therapeutics, and Paratek Pharmaceuticals and received research support from Insmed, Inc., AN2 Therapeutics, Paratek Pharmaceuticals, Electromed, Inc., Hillrom, and Zambon. R. J. W. received research support from Insmed, Inc. K. L. W. received support as a consultant from Insmed, Inc., AN2 Therapeutics, Paratek Pharmaceuticals, RedHill Biopharma, Renovion, Inc., and Spero Therapeutics and received research support from Insmed, Inc., AN2 Therapeutics, Paratek Pharmaceuticals, RedHill Biopharma, and Renovion, Inc. None declared (S. A. R. S., B. A. B.-E., A. E. B., P. E. S., C. F., L. S.).

Figures

Figure 1
Figure 1
Consolidated Standards of Reporting Trials (CONSORT) diagram showing progression of patients in the study. aAll 14 screening failures were the result of no positive culture findings for M abscessus during the screening visit.
See this image and copyright information in PMC

References

    1. Winthrop K.L., Marras T.K., Adjemian J., Zhang H., Wang P., Zhang Q. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan, 2008-2015. Ann Am Thorac Soc. 2020;17(2):178–185. - PMC - PubMed
    1. Prevots D.R., Marras T.K. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015;36(1):13–34. - PMC - PubMed
    1. Wagner D.L.M., Cooray S., Ringshausen F.C., Morimoto K., Koh W.J., Thomson R. In: Nontuberculous Mycobacterial Disease. Respiratory Medicine. Griffith D.E., editor. Humana Press, Cham; 2019. Global epidemiology of NTM disease (except Northern America) pp. 163–260.
    1. Tortoli E., Kohl T.A., Brown-Elliott B.A., et al. Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii and designation of Mycobacteriumabscessus subsp. massiliense comb. nov. Int J Syst Evol Microbiol. 2016;66(11):4471–4479. - PubMed
    1. Griffith D.E., Brown-Elliott B.A., Benwill J.L., Wallace R.J., Jr., Mycobacterium abscessus “Pleased to meet you, hope you guess my name . . . .”. Ann Am Thorac Soc. 2015;12(3):436–439. - PubMed

Publication types

Associated data